摘要
目的观察吉西他滨(gemcitabine,GEM)联合卡铂(carboplatin,CBP)在晚期老年非小细胞肺癌临床疗效及毒性反应。方法60例晚期老年(≥65岁)非小细胞肺癌分成吉西他滨组(A组)和长春瑞滨组(B组),A组:吉西他滨+卡铂(30例),B组:长春瑞滨+顺铂(30例)。吉西他滨1000mg/m2,第1、8天,卡铂300mg/m2,第1天,每3周为1个周期;长春瑞滨25mg/m2,第1、8天,顺铂80mg/m2,第1、3天,每3周为1个周期。结果60例患者的症状均有不同程度的改善。A组及B组有效率为43.3%及36.7%,两组间无显著性差异(P>0.05)。中位生存期(median survival time,MST)、疾病缓解时间(disease median response time,DPT)A组及B组分别为9.2个月、8.9个月及4.4个月、4.2个月。1年生存率A组及B组分别为45·5%、41.6%。两组间无显著性差异(P>0.05)。毒性反应:B组白细胞Ⅲ/Ⅳ度下降发生率和静脉炎的发生率明显高于A组(P<0.05)。结论吉西他滨+卡铂与长春瑞滨+顺铂对晚期老年非小细胞肺癌的近期临床疗效相近,MST、DTP、1年生存率均相似,但吉西他滨组耐受性及毒性反应低于长春瑞滨组。吉西他滨联合卡铂方案可作为治疗晚期老年非小细胞肺癌有效的化疗方案。
Objective To evaluate and the effects and safety of gemcitabine plus carboplatin （GEM ＋ CBP） regimen and navebine plus cisplatin （ NVB ＋ DDP） regimens for aged patients with advanced non-small cell lung cancer （NSCLC）. Methods The 60 cases of aged patients with NSCLC, over 65 years old and 35 cases beyond 70, were randomly and equally divided into 2 groups. Group A received 1 000 mg/m^2 GEM at day 1 and 8, and 300 mg/m^2 CBP at day 1. Group B underwent the therapy of 25 mg/m2 NVB at day 1 and 8, and 80 mg/m2 DDP at day 1 and 3. Both were treated with 3 weeks as a cycle. Results Overall response rate was 43.3% in group A and 36.7% in group B without significant difference. The median survival time （MST） and disease median response time（DPT） was 9.2 and 4.4 months in A group, and 8.9 and 4.2 months in B group. MST, DPT and one year survival rate were similar in 2 groups. Toxicities： WHO grade Ⅲ/Ⅳ leukopenia occurred in B group was higher than that in A group. The frequence of phlebitis was significantly higher in group B than group A （P 〈 0.05 ）. Conclusion There are similar outcomes in the overall response rates, MST, DRT and one year survival rate in 2 groups, but GEM ＋ CBP regimen has a better tolerability and lower toxicities. GEM ＋ CBP regimen is a better chemotherapeutic regimen for aged NSCLC patients.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2007年第19期1913-1915,共3页
Journal of Third Military Medical University
关键词
非小细胞肺癌
吉西他滨
老年
化疗
non-small cell lung cancer
old age
drug therapy
gemcitabine
